title: ChimeriVax-West Nile vaccine.
abstract: Acambis (formerly Peptide Therapeutics) is developing ChimeriVax-West Nile, a recombinant live-attenuated vaccine which incorporates their ChimeriVax platform technology, for the potential prevention of West Nile virus infection [373463], [328969]. A phase II clinical trial to assess the safety, tolerability and immunogenicity of different doses of ChimeriVax-West Nile is underway [642090], [775386].
authors.affiliation: School of Molecular and Microbial Sciences, The University of Queensland, St Lucia, Queensland 4072, Australia. roy.hall@uq.edu.au
authors.forename: Roy A
authors.initials: RA
authors.lastname: Hall
authors.forename: Alexander A
authors.initials: AA
authors.lastname: Khromykh
mesh_terms: D000818:Animals; D004353:Drug Evaluation, Preclinical; D006801:Humans; D014901:West Nile Fever / Q000276:immunology / Q000517:prevention & control*; D053060:West Nile Virus Vaccines / Q000009:adverse effects / Q000276:immunology*; D014902:West Nile virus / Q000276:immunology*
chemical_list: C445780:ChimeriVax; D053060:West Nile Virus Vaccines